Fig. 1From: Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cellsCell based changes: a significant increase in percentage of CD133 positive hematopoietic progenitor cells (a, p = 0.004). A trend in increased dual positive CD34+ and CD133+ cells, close to statistical significance (b; p = 0.07) is observed in INSTI (n = 13) group as compared to NNRTI (n = 6) groupBack to article page